Advertisement

Breast Cancer Research and Treatment

, Volume 126, Issue 1, pp 149–155 | Cite as

Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study

  • Aditya Bardia
  • Janet E. Olson
  • Celine M. Vachon
  • DeAnn Lazovich
  • Robert A. Vierkant
  • Alice H. Wang
  • Paul J. Limburg
  • Kristin E. Anderson
  • James R. CerhanEmail author
Epidemiology

Abstract

Aspirin and other non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit aromatase activity and thus could selectively lower incidence of hormone receptor positive tumors. We assessed whether the association of aspirin and other NSAIDs with postmenopausal breast cancer risk differs by estrogen and progesterone receptor (ER and PR) status of the tumor. A population-based cohort of 26,580 postmenopausal women was linked to a SEER Cancer Registry to identify incident breast cancers. Regular use of aspirin and other NSAIDs was reported on a self-administered questionnaire mailed in 1992. Cox proportional hazards models were used to estimate multivariate relative risks (RRs) and 95% confidence intervals (CIs) of breast cancer incidence overall and by ER and PR status, adjusting for multiple breast cancer risk factors. Through 2005, 1,581 incident breast cancer cases were observed. Compared to aspirin never users, women who regularly consumed aspirin had a lower risk of breast cancer (RR = 0.80; 95% CI: 0.71–0.90), and there was evidence for lower risk with increasing frequency of use (RR = 0.71 for aspirin use 6 or more times/week vs. never use; P trend = 0.00001). Inverse associations for regular aspirin use were observed for ER+ (RR = 0.77; 95% CI 0.67–0.89), ER− (RR = 0.78; 95% CI 0.56–1.08), PR+ (RR = 0.79; 95% CI 0.68–0.92), and PR− (RR = 0.73; 95% CI 0.56–0.95) breast cancers. In contrast, use of other NSAIDs was not associated with breast cancer incidence overall (RR = 0.95, 95% CI: 0.85–1.07), or by ER or PR status. Aspirin, but not other NSAID use, was associated with about 20% lower risk of postmenopausal breast cancer and did not vary by ER or PR status of the tumor, suggesting that the hypothesized protective effects of aspirin may either be through cellular pathways independent of estrogen or progesterone signaling, or on tumor microenvironment.

Keywords

Breast cancer Aspirin NSAIDs Hormone receptors Prevention 

Notes

Acknowledgments

We would like to thank Dr. Vered Stearns, Associate Professor, Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, for her expert comments and feedback. We thank Sondra Buehler for editorial assistance. This study was supported in part by a grant (R01 CA39742), National Cancer Institute (NCI), USA.

Conflict of interest

None

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMedGoogle Scholar
  2. 2.
    American Cancer Society. Breast cancer facts & figures 2009–2010. American Cancer Society, Inc., AtlantaGoogle Scholar
  3. 3.
    Harris RE, Beebe-Donk J, Doss H, Burr Doss D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13:559–583PubMedGoogle Scholar
  4. 4.
    Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–507CrossRefPubMedGoogle Scholar
  5. 5.
    Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373:1301–1309CrossRefPubMedGoogle Scholar
  6. 6.
    Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, Vogel VG, Weissfeld JL (2008) Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:680–687CrossRefPubMedGoogle Scholar
  7. 7.
    Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE (2010) Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 19:1033–1041CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805–812CrossRefPubMedGoogle Scholar
  9. 9.
    Harris RE, Namboodiri KK, Farrar WB (1996) Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7:203–205CrossRefPubMedGoogle Scholar
  10. 10.
    Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S (1999) The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 29:72–76CrossRefPubMedGoogle Scholar
  11. 11.
    Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433–2440CrossRefPubMedGoogle Scholar
  12. 12.
    Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146CrossRefPubMedGoogle Scholar
  13. 13.
    Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M (2005) Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 5:159CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 162:165–170CrossRefPubMedGoogle Scholar
  15. 15.
    Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B (2007) Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 166:709–716CrossRefPubMedGoogle Scholar
  16. 16.
    Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88:988–993CrossRefPubMedGoogle Scholar
  17. 17.
    Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320:1642–1646CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, Patel AV, Flanders WD, Calle EE (2005) Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 14:261–264CrossRefPubMedGoogle Scholar
  19. 19.
    Johnson TW, Anderson KE, Lazovich D, Folsom AR (2002) Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of post-menopausal breast cancer. Cancer Epidemiol Biomarkers Prev 11:1586–1591PubMedGoogle Scholar
  20. 20.
    Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA (2008) Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health—AARP Diet and Health Study. Breast Cancer Res 10:R38CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294:47–55CrossRefPubMedGoogle Scholar
  22. 22.
    Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 166:1150–1158CrossRefPubMedGoogle Scholar
  23. 23.
    Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121:211–215CrossRefPubMedGoogle Scholar
  24. 24.
    Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 17:88–96CrossRefPubMedGoogle Scholar
  25. 25.
    Folsom AR, Kaye SA, Prineas RJ, Potter JD, Gapstur SM, Wallace RB (1990) Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol 131:794–803PubMedGoogle Scholar
  26. 26.
    Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF et al (2008) SEER cancer statistics review, 1975–2005. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site
  27. 27.
    Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145:72–80CrossRefPubMedGoogle Scholar
  28. 28.
    Zhao YS, Zhu S, Li XW, Wang F, Hu FL, Li DD, Zhang WC, Li X (2009) Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 117:141–150CrossRefPubMedGoogle Scholar
  29. 29.
    Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Res 63:6096–6101PubMedGoogle Scholar
  30. 30.
    Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28:1467–1472CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3:28CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon MS, Malone KE, Strom BL, Ursin G, Marchbanks PA et al (2009) Breast cancer receptor status: do results from a centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol Biomarkers Prev 18:2214–2220CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Aditya Bardia
    • 1
  • Janet E. Olson
    • 2
  • Celine M. Vachon
    • 2
  • DeAnn Lazovich
    • 3
  • Robert A. Vierkant
    • 2
  • Alice H. Wang
    • 2
  • Paul J. Limburg
    • 2
  • Kristin E. Anderson
    • 3
  • James R. Cerhan
    • 2
    Email author
  1. 1.Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA
  2. 2.Department of Health Sciences Research, College of MedicineMayo ClinicRochesterUSA
  3. 3.School of Public HealthUniversity of MinnesotaMinneapolisUSA

Personalised recommendations